Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 31 August 1979:
Vol. 205. no. 4409, pp. 913 - 915
DOI: 10.1126/science.472712
Prev | Table of Contents | Next

Articles

Science, Vol 205, Issue 4409, 913-915
Copyright © 1979 by American Association for the Advancement of Science

articles

Mullerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer

PK Donahoe, DA Swann, A Hayashi, and MD Sullivan

A significant cytotoxicity index was obtained when human ovarian cancer cells in a microcytotoxicity assay were exposed during the S (DNA-synthesizing) phase of the cell cycle to purified fractions of testis exhibiting high Mullerian inhibiting substance bioactivity. The same effect was not observed when these fractions were tested against human glioblastoma or fibroblast lines. Most human ovarian cancers are said to resemble Mullerian tissues histologically. Mullerian inhibiting substance may thus deserve further study as a potential chemotherapeutic agent.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
R. Pieretti-Vanmarcke, P. K. Donahoe, L. A. Pearsall, D. M. Dinulescu, D. C. Connolly, E. F. Halpern, M. V. Seiden, and D. T. MacLaughlin (2006)
PNAS 103, 17426-17431
   Abstract »    Full Text »    PDF »
Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo.
R. Pieretti-Vanmarcke, P. K. Donahoe, P. Szotek, T. Manganaro, M. K. Lorenzen, J. Lorenzen, D. C. Connolly, E. F. Halpern, and D. T. MacLaughlin (2006)
Clin. Cancer Res. 12, 1593-1598
   Abstract »    Full Text »    PDF »
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
T. U. Barbie, D. A. Barbie, D. T. MacLaughlin, S. Maheswaran, and P. K. Donahoe (2003)
PNAS 100, 15601-15606
   Abstract »    Full Text »    PDF »
Highly Purified Mullerian Inhibiting Substance Inhibits Human Ovarian Cancer in Vivo.
A. E. Stephen, L. A. Pearsall, B. P. Christian, P. K. Donahoe, J. P. Vacanti, and D. T. MacLaughlin (2002)
Clin. Cancer Res. 8, 2640-2646
   Abstract »    Full Text »    PDF »
Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications.
J. Teixeira, S. Maheswaran, and P. K. Donahoe (2001)
Endocr. Rev. 22, 657-674
   Abstract »    Full Text »    PDF »
Human Mullerian-Inhibiting Substance Promoter Contains a Functional TFII-I-Binding Initiator.
N. Morikawa, T. R. Clarke, C. D. Novina, K. Watanabe, C. Haqq, M. Weiss, A. L. Roy, and P. K. Donahoe (2000)
Biol Reprod 63, 1075-1083
   Abstract »    Full Text »
Human Ovarian Cancer, Cell Lines, and Primary Ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and Are Responsive to MIS.
P. T. Masiakos, D. T. MacLaughlin, S. Maheswaran, J. Teixeira, A. F. Fuller Jr., P. C. Shah, D. J. Kehas, M. K. Kenneally, D. M. Dombkowski, T. U. Ha, et al. (1999)
Clin. Cancer Res. 5, 3488-3499
   Abstract »    Full Text »    PDF »
Regulation of Sexual Dimorphism in Mammals.
C. M. HAQQ and P. K. DONAHOE (1998)
Physiol Rev 78, 1-33
   Abstract »    Full Text »    PDF »
Development of Mullerian Inhibiting Substance as an Anti-cancer Drug.
R.L. Cate, E.G. Ninfa, D.J. Pratt, D.T. MacLaughlin, and P.K. Donahoe (1986)
Cold Spring Harb Symp Quant Biol 51, 641-647
   Abstract »    PDF »
Phosphorylation events during Mullerian duct regression.
J. Hutson, M. Fallat, S Kamagata, P. Donahoe, and G. Budzik (1984)
Science 223, 586-589
   Abstract »    PDF »
Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.
A. E. Stephen, P. T. Masiakos, D. L. Segev, J. P. Vacanti, P. K. Donahoe, and D. T. MacLaughlin (2001)
PNAS 98, 3214-3219
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)